Imatinib Zentiva (Imatinib Mesilate)

Imatinib Zentiva acts on abnormal tyrosine‑kinase signaling pathways that drive certain hematologic and solid tumours.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival.
• Gastrointestinal stromal tumor (GIST): blocks KIT‑driven tumor growth and prolongs progression‑free survival.
• Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used with chemotherapy.

• Imatinib mesilate selectively inhibits the BCR‑ABL fusion protein tyrosine kinase, as well as the c‑KIT and platelet‑derived growth factor receptor (PDGFR) kinases. By blocking these enzymes, it prevents downstream signaling that drives uncontrolled cell division, thereby suppressing malignant proliferation in targeted cancers.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or face.
• Fatigue: persistent tiredness.
• Diarrhea: loose stools.
• Rash: skin irritation or redness.
• Muscle cramps: involuntary tightening of muscles.

Serious or Rare Side Effects

• Neutropenia: dangerously low white‑blood‑cell count.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced heart pumping ability.
• Severe hemorrhage: abnormal bleeding.
• Interstitial lung disease: inflammation of lung tissue.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.

• Blood count monitoring: check complete blood count frequently to detect cytopenias.
• Liver function assessment: evaluate hepatic enzymes before and during treatment.
• Cardiac evaluation: perform ECG or echocardiogram in patients with pre‑existing heart disease.
• Hypersensitivity warning: discontinue if severe allergic reaction occurs.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels and efficacy.
• Warfarin: concurrent use can enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., midazolam, tacrolimus): may require dose adjustment of the co‑administered drug.
• Diuretics (e.g., furosemide): can increase plasma concentration of imatinib, warranting close monitoring.